Skip to content

Omeros OMER PP&E (Net)

PP&E (Net) at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$342K-43.7%
Immunome logo
ImmunomeIMNM
$17.08M+55.9%
Vor Biopharma logo
Vor BiopharmaVOR
$565K-90.6%
Annexon logo
AnnexonANNX
$10.11M-17.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$38M-17.4%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$274K+43.5%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's PP&E (net)?
Omeros (OMER) reported PP&E (net) of $1.53M in Q1 2026.
How has Omeros's PP&E (net) changed year-over-year?
Omeros's PP&E (net) decreased by 36.8% year-over-year, from $2.42M to $1.53M.
What is the long-term trend for Omeros's PP&E (net)?
Over 5 years (2020 to 2025), Omeros's PP&E (net) has grown at a -7.1% compound annual growth rate (CAGR), from $2.55M to $1.77M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.